Cargando…
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...
Autores principales: | Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449563/ https://www.ncbi.nlm.nih.gov/pubmed/31807773 http://dx.doi.org/10.1093/cvr/cvz278 |
Ejemplares similares
-
A key role for the novel coronary artery disease gene JCAD in atherosclerosis via shear stress mechanotransduction
por: Douglas, Gillian, et al.
Publicado: (2020) -
Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective
por: Lelieveld, Jos, et al.
Publicado: (2020) -
Is myocardial work the piece of puzzle that we missed?
por: Tadic, Marijana, et al.
Publicado: (2022) -
Changes in myocardial work associated with pediatric kidney transplantation: A pilot study of short‐term postoperative effect
por: Xiao, Fei, et al.
Publicado: (2022) -
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)